AvMed

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: **The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request**. All other information may be filled in by office staff; **fax to 1-305-671-0200**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

Drug Requested: Bimzelx® (bimekizumab-bkzx) **(Pharmacy)**

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member AvMed #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy**: _____

Diagnosis: _____ **ICD Code, if applicable:** _____

Weight (if applicable): _____ **Date weight obtained:** _____

NOTE: The Health Plan considers the use of concomitant therapy with more than one biologic immunomodulator (e.g., Dupixent, Entyvio, Humira, Rinvoq, Stelara) prescribed for the same or different indications to be experimental and investigational. Safety and efficacy of these combinations has **NOT** been established and will **NOT** be permitted.

❑ Will the member be discontinuing a previously prescribed biologic if approved for requested medication?

❑ Yes **OR** ❑ No

❑ If yes, please list the medication that will be discontinued and the medication that will be initiated upon approval along with the corresponding effective date.

Medication to be discontinued: _____ **Effective date:** _____

Medication to be initiated: _____ **Effective date:** _____

(Continued on next page)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

❑ Diagnosis: Moderate-to-Severe Plaque Psoriasis

Dosing: SUBQ: 320 mg (given as two 160 mg injections) once every 4 weeks for the first 16 weeks (5 doses), and then every 8 weeks thereafter.

- ❑ Member has a diagnosis of moderate-to-severe **plaque psoriasis**
- ❑ Prescribed by or in consultation with a **Dermatologist**
- ❑ Member tried and failed at least **ONE** of either Phototherapy or Alternative Systemic Therapy for at least **three (3) months (check each tried below)**:

❑ **Phototherapy:**	❑ **Alternative Systemic Therapy:**
❑ **UV Light Therapy** ❑ NB UV-B ❑ PUVA	❑ **Oral Medications** ❑ acitretin ❑ methotrexate ❑ cyclosporine

- ❑ Member meets **ONE** of the following:
  - ❑ Member tried and failed, has a contraindication, or intolerance to **TWO** of the **PREFERRED** biologics below **(verified by chart notes or pharmacy paid claims)**:

❑ Preferred adalimumab product*	❑ Enbrel®	❑ Otezla®	❑ Skyrizi®
❑ Sotyktu™	❑ Stelara®	❑ Taltz®	❑ Tremfya®

  ***NOTE: COMM/FAMIS preferreds = Humira/Cyltezo/Yuflyma -** Humira NDC's starting with 83457 are not approved, NDC's starting with 00074 (MFG: Abbvie) are preferred; **SG/IP/HIX preferreds = Simlandi or adalimumab-adbm**

  - ❑ Member has been established on Bimzelx® for at least 90 days **AND** prescription claims history indicates **at least a 90-day supply of Bimzelx was dispensed within the past 130 days (verified by chart notes or pharmacy paid claims)**

❑ Diagnosis: Active Psoriatic Arthritis

Dosing: SUBQ: 160 mg once every 4 weeks. **NOTE:** For patients with psoriatic arthritis and coexisting moderate to severe plaque psoriasis, use the dosing regimen for plaque psoriasis

- ❑ Member has a diagnosis of active **psoriatic arthritis**
- ❑ Prescribed by or in consultation with a **Rheumatologist**

(Continued on next page)

- ❑ Member has tried and failed at least **ONE** of the following **DMARD** therapies for at least **three (3) months**
  - ❑ cyclosporine
  - ❑ leflunomide
  - ❑ methotrexate
  - ❑ sulfasalazine
- ❑ Member meets **ONE** of the following:
  - ❑ Member tried and failed, has a contraindication, or intolerance to **TWO** of the **PREFERRED** biologics below **(verified by chart notes or pharmacy paid claims)**:

❑ Preferred adalimumab product*	❑ Enbrel®	❑ Otezla®	❑ Rinvoq®/ Rinvoq® LQ
	❑ Skyrizi®	❑ Stelara®	❑ Taltz®
	❑ Xeljanz®/XR®	❑ Tremfya®	

***NOTE: COMM/FAMIS preferreds = Humira/Cyltezo/Yuflyma -** Humira NDC's starting with 83457 are not approved, NDC's starting with 00074 (MFG: Abbvie) are preferred; **SG/IP/HIX preferreds = Simlandi or adalimumab-adbm**

  - ❑ Member has been established on Bimzelx® for at least 90 days **AND** prescription claims history indicates **at least a 90-day supply of Bimzelx was dispensed within the past 130 days (verified by chart notes or pharmacy paid claims)**

❑ Diagnosis: Active Non-Radiographic Axial Spondyloarthritis

Dosing: SUBQ: 160 mg once every 4 weeks.

- ❑ Member has a diagnosis of active non-radiographic **axial spondyloarthritis**
- ❑ Prescribed by or in consultation with a **Rheumatologist**
- ❑ Member has at least **ONE** of the following objective signs of inflammation:
  - ❑ C-reactive protein [CRP] levels above the upper limit of normal
  - ❑ Sacroiliitis on magnetic resonance imaging [MRI] (indicative of inflammatory disease, but without definitive radiographic evidence of structural damage on sacroiliac joints)
- ❑ Member tried and failed, has a contraindication, or intolerance to **TWO** NSAIDs
- ❑ Member meets **ONE** of the following:
  - ❑ Member tried and failed, has a contraindication, or intolerance to **TWO** of the following **(verified by chart notes or pharmacy paid claims)**:

❑ Cimzia®	❑ Rinvoq®	❑ Taltz®

  - ❑ Member has been established on Bimzelx® for at least 90 days **AND** prescription claims history indicates **at least a 90-day supply of Bimzelx was dispensed within the past 130 days (verified by chart notes or pharmacy paid claims)**

(Continued on next page)

❑ Diagnosis: Active Ankylosing Spondylitis

Dosing: SUBQ: 160 mg once every 4 weeks.

- ❑ Member has a diagnosis of active **ankylosing spondylitis**
- ❑ Prescribed by or in consultation with a **Rheumatologist**
- ❑ Member tried and failed, has a contraindication, or intolerance to **TWO** NSAIDs
- ❑ Member meets **ONE** of the following:
  - ❑ Member tried and failed, has a contraindication, or intolerance to **TWO** of the **PREFERRED** biologics below **(verified by chart notes or pharmacy paid claims)**:

❑ Preferred adalimumab product*	❑ Enbrel®	❑ Rinvoq®
❑ Taltz®	❑ Xeljanz®/XR®	

***NOTE: COMM/FAMIS preferreds = Humira/Cyltezo/Yuflyma -** Humira NDC's starting with 83457 are not approved, NDC's starting with 00074 (MFG: Abbvie) are preferred; **SG/IP/HIX preferreds = Simlandi or adalimumab-adbm**

  - ❑ Member has been established on Bimzelx® for at least 90 days **AND** prescription claims history indicates **at least a 90-day supply of Bimzelx was dispensed within the past 130 days (verified by chart notes or pharmacy paid claims)**

❑ Diagnosis: Moderate-to-Severe Hidradenitis Suppurativa

Dosing: SUBQ: 320 mg once every 2 weeks for the first 16 weeks (9 doses), and then every 4 weeks thereafter.

- ❑ Member has a diagnosis of moderate-to-severe **hidradenitis suppurativa**
- ❑ Prescribed by or in consultation with a **Dermatologist**
- ❑ Member tried and failed a 90-day course of oral antibiotics (e.g., tetracycline, minocycline, doxycycline or clindamycin, rifampin) for treatment of HS **(within the last 9 months)**

  Name of Antibiotic & Date: _____

- ❑ Member meets **ONE** of the following:
  - ❑ Member tried and failed, has a contraindication, or intolerance to **BOTH PREFERRED** biologics below **(verified by chart notes or pharmacy paid claims)**:
    - ❑ **ONE** preferred adalimumab product [**NOTE: COMM/FAMIS preferreds = Humira/Cyltezo/Yuflyma -** Humira NDC's starting with 83457 are not approved, NDC's starting with 00074 (MFG: Abbvie) are preferred; **SG/IP/HIX preferreds = Simlandi or adalimumab-adbm**]
    - ❑ Cosentyx® SQ (secukinumab)
  - ❑ Member has been established on Bimzelx® for at least 90 days **AND** prescription claims history indicates **at least a 90-day supply of Bimzelx was dispensed within the past 130 days (verified by chart notes or pharmacy paid claims)**

(Continued on next page)

Medication being provided by Specialty Pharmacy – Proprium Rx

Not all drugs may be covered under every Plan

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****

***Approved by Pharmacy and Therapeutics Committee:** ~~1/18/2024; 11/21/2024;~~ **1/23/2025**
REVISED/UPDATED/REFORMATTED: ~~2/9/2024; 12/16/2024;~~ **2/18/2025**